Document Detail


Blue toe syndrome and sunitinib.
MedLine Citation:
PMID:  21136131     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We present a patient with metastatic renal cell carcinoma treated with sunitinib, a multitargeted tyrosine kinase inhibitor. The patient experienced bilateral blue toe syndrome which we related to sunitinib use. Discontinuation of sunitinib to lower the patient's prothrombotic state and increase the ability to form collaterals, together with the addition of low-molecular-weight heparin to treat the occluding thrombi, resulted in waning of the blue toe syndrome. This case adds to the accumulating evidence of possible untoward cardiovascular side effects that should be taken into consideration in patients on tyrosine kinase inhibitors such as sunitinib.
Authors:
Pieter G Postema; Madelien V Regeer; Paul R van der Valk; Erik S G Stroes; Dick J Richel
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-12-08
Journal Detail:
Title:  International journal of clinical oncology     Volume:  16     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-13     Completed Date:  2012-02-13     Revised Date:  2012-12-13    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  574-6     Citation Subset:  IM    
Affiliation:
Department of Oncology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects*,  therapeutic use
Blue Toe Syndrome / chemically induced*,  pathology
Carcinoma, Renal Cell / drug therapy*,  pathology
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Indoles / adverse effects*,  therapeutic use
Kidney Neoplasms / drug therapy*,  pathology
Male
Middle Aged
Neoplasm Metastasis
Protein Kinase Inhibitors / adverse effects,  therapeutic use
Pyrroles / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Heparin, Low-Molecular-Weight; 0/Indoles; 0/Protein Kinase Inhibitors; 0/Pyrroles; 0/sunitinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intraindividual comparison of gadolinium- and iodine-enhanced 64-slice multidetector CT pulmonary an...
Next Document:  A survey of disclosure of diagnosis to patients with glioma in Japan.